Ironwood Pharmaceuticals Inc (IRWD)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Ironwood Pharmaceuticals Inc (IRWD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012204
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:71
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Ironwood Pharmaceuticals Inc (Ironwood) is a commercial biotechnology company that discovers, develops and commercializes medicines for gastrointestinal (GI) disorders. The company’s marketed products consist of Linzess (linaclotide), an oral capsule for the treatment of irritable bowel syndrome with constipation or chronic idiopathic constipation in adult men and women; and Zurampic (lesinurad) for the treatment of hyperuricemia associated with gout. Ironwood also evaluates linaclotide in other indications, new formulations and in combination with other products in various GI conditions. Its pipeline product portfolio comprises Duzallo (lesinurad and allopurinol), a combination product for the treatment of hyperuricemia in patients with uncontrolled gout; and other development programs. Ironwood is headquartered in Cambridge, Massachusetts, the US.

Ironwood Pharmaceuticals Inc (IRWD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Ironwood Pharma Enters into Co-Promotion Agreement with Allergan 12
Ironwood Pharma And Protagonist Therapeutics Expand Peptide Drug Discovery Collaboration 13
AstraZeneca Enters Into Co-Development Agreement With Ironwood Pharma For Linaclotide 14
AstraZeneca Enters Into Co-Promotion Agreement With Ironwood Pharma For Nexium 16
Ironwood Pharma Enters Into Collaboration With Protagonist Therapeutics 17
Licensing Agreements 18
Ironwood Pharma Enters into Licensing Agreement with AstraZeneca 18
Ironwood Pharma Enters Into Licensing Agreement With Depomed 19
Synergy Pharma Enters Into Agreement With Ironwood Pharma For Plecanatide 20
Equity Offering 21
Ironwood Pharma Plans to Raise Funds through Public Offering of Securities 21
Ironwood Pharma Raises USD201.3 Million in Public Offering of Shares 22
Ironwood Pharma Completes Partial Exercise Of Underwriter’s Option For Public Offering Of Shares For US$146 Million 24
Ironwood Pharma Completes Public Offering Of Common Stock For US$91 Million 26
Debt Offering 28
Ironwood Pharma Raises USD150 Million in Private Placement of 8.375% Notes Due 2026 28
Ironwood Pharma Raises USD335.7 Million in Private Placement of 2.25% Notes Due 2022 29
Ironwood Pharma Completes Private Placement Of Notes Due 2024 For US$175 Million 30
Ironwood Pharmaceuticals Inc – Key Competitors 31
Ironwood Pharmaceuticals Inc – Key Employees 32
Ironwood Pharmaceuticals Inc – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Financial Announcements 34
Nov 02, 2017: Ironwood Pharmaceuticals Provides Third Quarter 2017 Investor Update 34
Aug 03, 2017: Ironwood Pharmaceuticals Provides Second Quarter 2017 Investor Update 39
May 08, 2017: Ironwood Pharmaceuticals Provides First Quarter 2017 Investor Update 41
Feb 21, 2017: Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2016 Investor Update 43
Nov 03, 2016: Ironwood Pharmaceuticals Provides Third Quarter 2016 Investor Update 47
Aug 04, 2016: Ironwood Pharmaceuticals Provides Second Quarter 2016 Investor Update 50
May 09, 2016: Ironwood Pharmaceuticals Provides First Quarter 2016 Investor Update 54
Feb 18, 2016: Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2015 Investor Update 57
Corporate Communications 60
Nov 28, 2017: Ironwood Pharmaceuticals Strengthens Executive Leadership Team 60
Sep 06, 2017: Ironwood Pharmaceuticals Announces Leadership Change 61
Apr 06, 2017: Ironwood Pharmaceuticals Appoints Dr. Christopher Wright as Senior Vice President of Global Development and Chief Development Officer 62
Jan 04, 2017: Ironwood Pharmaceuticals Appoints Amy Schulman to Board of Directors 63
Apr 07, 2016: Ironwood Pharmaceuticals Appoints Andrew Dreyfus to Board of Directors 64
Product News 65
03/30/2016: Ironwood Pharmaceuticals to Present Clinical Data on sGC Stimulator IW-1973 at Upcoming Scientific Conferences 65
01/15/2016: Link Between Obesity and Increased Risk of Colorectal Cancer Revealed 66
Clinical Trials 68
Feb 18, 2016: Ironwood Pharmaceuticals Progresses Vascular and Fibrotic Disease Platform with Positive Top-Line Phase Ia Data on Soluble Guanylate Cyclase Stimulator IW-1701 68
Other Significant Developments 69
Jan 08, 2017: Ironwood Pharmaceuticals Demonstrates Strong Execution on Strategy to Build Top-Performing Commercial Biotech 69
Appendix 71
Methodology 71
About GlobalData 71
Contact Us 71
Disclaimer 71

List of Tables
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Ironwood Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Ironwood Pharma Enters into Co-Promotion Agreement with Allergan 12
Ironwood Pharma And Protagonist Therapeutics Expand Peptide Drug Discovery Collaboration 13
AstraZeneca Enters Into Co-Development Agreement With Ironwood Pharma For Linaclotide 14
AstraZeneca Enters Into Co-Promotion Agreement With Ironwood Pharma For Nexium 16
Ironwood Pharma Enters Into Collaboration With Protagonist Therapeutics 17
Ironwood Pharma Enters into Licensing Agreement with AstraZeneca 18
Ironwood Pharma Enters Into Licensing Agreement With Depomed 19
Synergy Pharma Enters Into Agreement With Ironwood Pharma For Plecanatide 20
Ironwood Pharma Plans to Raise Funds through Public Offering of Securities 21
Ironwood Pharma Raises USD201.3 Million in Public Offering of Shares 22
Ironwood Pharma Completes Partial Exercise Of Underwriter's Option For Public Offering Of Shares For US$146 Million 24
Ironwood Pharma Completes Public Offering Of Common Stock For US$91 Million 26
Ironwood Pharma Raises USD150 Million in Private Placement of 8.375% Notes Due 2026 28
Ironwood Pharma Raises USD335.7 Million in Private Placement of 2.25% Notes Due 2022 29
Ironwood Pharma Completes Private Placement Of Notes Due 2024 For US$175 Million 30
Ironwood Pharmaceuticals Inc, Key Competitors 31
Ironwood Pharmaceuticals Inc, Key Employees 32
Ironwood Pharmaceuticals Inc, Subsidiaries 33

★海外企業調査レポート[Ironwood Pharmaceuticals Inc (IRWD)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Target Corp:企業の戦略・SWOT・財務情報
    Target Corp - Strategy, SWOT and Corporate Finance Report Summary Target Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • BioNTech AG:製薬・医療:M&Aディール及び事業提携情報
    Summary BioNTech AG (BioNTech) is a biopharmaceutical company that develops biomarker based diagnostics. The company’s products include RNXtract and mammatyper, and cell and gene therapies. It pipeline products include BioNTech mRNA pharmaceuticals, BioNTech cell and gene, BioNTech small molecules a …
  • Camlin Fine Sciences Limited:戦略・SWOT・企業財務分析
    Camlin Fine Sciences Limited - Strategy, SWOT and Corporate Finance Report Summary Camlin Fine Sciences Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • InSphero AG:医療機器:M&Aディール及び事業提携情報
    Summary InSphero AG (InSphero) is a biotechnology company that offers production, culture and assessment of organotypic 3D cell culture models. The company’s product portfolio includes microtissues kits, cytotoxicity assay kits, and microtissue spheroids, among others. Its patented 3D cell culture p …
  • Impinj Inc (PI):企業の財務・戦略的SWOT分析
    Impinj Inc (PI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Caprion Biosciences Inc-医療機器分野:企業M&A・提携分析
    Summary Caprion Biosciences Inc (Caprion) is a provider of proteomics and immune monitoring services. The company’s proteomic based services include neo-epitope discovery and characterization, biomarker discovery, fit-for-purpose assays, host cell protein detection and PK assays, among others. It of …
  • Christian Dior SE:戦略・SWOT・企業財務分析
    Christian Dior SE - Strategy, SWOT and Corporate Finance Report Summary Christian Dior SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Amara Raja Batteries Ltd (AMARAJABAT):企業の財務・戦略的SWOT分析
    Summary Amara Raja Batteries Ltd (Amara Raja) operates as a manufacturer of lead-acid storage batteries. The company operates through two sectors automotive battery and industrial battery sectors. Its automotive battery sector offers two-wheeler batteries, four-wheeler batteries and tubular batterie …
  • Rehrig Pacific Company:企業の戦略的SWOT分析
    Rehrig Pacific Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Enzo Biochem Inc (ENZ):企業の製品パイプライン分析
    Summary Enzo Biochem Inc (Enzo Biochem) is a life sciences and biotechnology company with a focus on harnessing genetic processes for the development of research tools, therapeutics and diagnostics. It also provides reference laboratory services to the medical community. The company focuses on the d …
  • Anthelio Healthcare Solutions Inc.-医療機器分野:企業M&A・提携分析
    Summary Anthelio Healthcare Solutions Inc. (Anthelio), formerly PHNS Inc., is a healthcare IT service company that offers information technology and business process services to hospitals, physician practice groups and other healthcare providers. The company’s suite of software solutions include int …
  • XALT Energy LLC:企業の戦略的SWOT分析
    XALT Energy LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • The Kansai Electric Power Co, Incorporated:企業の戦略・SWOT・財務分析
    The Kansai Electric Power Co, Incorporated - Strategy, SWOT and Corporate Finance Report Summary The Kansai Electric Power Co, Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Securities Trust of Scotland plc (STS):企業の財務・戦略的SWOT分析
    Summary Securities Trust of Scotland plc (Securities Trust of Scotland) is a financial service provider that offers capital asset services, broking services, online stock broking services, and online dealing. The company raises income and long term capital growth through investment in a portfolio of …
  • Heartland Consumers Power District:企業の戦略的SWOT分析
    Heartland Consumers Power District - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Deutsche Telekom AG:戦略・SWOT・企業財務分析
    Deutsche Telekom AG - Strategy, SWOT and Corporate Finance Report Summary Deutsche Telekom AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Becton Dickinson and Co (BDX):企業の財務・戦略的SWOT分析
    Becton Dickinson and Co (BDX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Origin Energy Ltd (ORG)-石油・ガス分野:企業M&A・提携分析
    Summary Origin Energy Limited (Origin Energy) is an integrated energy company. It generates, supplies and distributes electricity; explores and develops natural gas reserves; and produces and sells gas. The company generates electricity from natural-gas fired, coal-fired, wind, solar, pumped water s …
  • BioDelivery Sciences International Inc (BDSI)-製薬・医療分野:企業M&A・提携分析
    Summary BioDelivery Sciences International Inc (BDSI) is a specialty pharmaceutical company which develops and commercializes products in the areas of addiction medicine and pain management. The company’s marketed products include fentanyl buccal soluble solution for breakthrough cancer pain; bupren …
  • Samsung Electronics Co Ltd (005930)-医療機器分野:企業M&A・提携分析
    Summary Samsung Electronics Co., Ltd. (Samsung) is a manufacturer of consumer electronics, information technology and mobile communications, and device solutions. The company’s product portfolio includes television (TV), washing machine, refrigerator, air conditioner, medical devices, monitor, print …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆